Clinical Trials Logo

Filter by:
NCT ID: NCT05768529 Recruiting - Clinical trials for Relapsed or Refractory Non-Hodgkin's Lymphoma

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: March 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a Phase I/II, single-arm, open-label clinical trial, and its primary objective of phase I and phase II is to evaluate the safety and efficacy of U16 Injection in the treatment of relapsed or refractory NHL,respectively.

NCT ID: NCT05768503 Recruiting - Clinical trials for Metastatic Microsatellite-stable Colorectal Cancer

Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Start date: March 1, 2023
Phase: Phase 3
Study type: Interventional

This is a randomized, controlled, multicenter phase Ⅲ study to evaluate the therapeutic efficacy and safety of chidamide + sintilimab + bevacizumab versus standard second-line FOLFIRI + bevacizumab therapy in subjects with advanced microsatellite stable colorectal cancer who have failed first-line oxaliplatin-containing standard therapy. The primary purpose is to compare the progression-free survival (PFS) of chidamide + sintilimab + bevacizumab versus standard second-line FOLFIRI + bevacizumab therapy for colorectal cancer, with a planned enrollment of 176 subjects with advanced microsatellite stable colorectal cancer who have failed first-line oxaliplatin-containing standard therapy.

NCT ID: NCT05768490 Recruiting - Brain Metastases Clinical Trials

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Start date: March 15, 2023
Phase: Phase 3
Study type: Interventional

This is a prospective, multicenter, randomized, controlled clinical study of NSCLC patients with intracranial oligo-metastatic EGFR-sensitive mutations treated with EGFR-TKI Almonertinib , according to the implementation time of brain radiotherapy. Patients were randomly divided into two groups, experimental group (early intervention group of brain radiotherapy) : the brain radiotherapy started within 1 month of TKI treatment, the brain radiotherapy here specifically refers to stereotactic radiotherapy; Control group (brain radiotherapy late intervention group) : Brain radiotherapy was given within 3 months after brain progression during TKI treatment. The differences in OS,iPFS, PFS, iORR, safety, neurocognitive function and quality of life between the two groups were compared.

NCT ID: NCT05768464 Recruiting - Clinical trials for Non-clear Renal Cell Carcinoma

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors

IUNU-RC
Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

The goal of this prospective, multicenter, single-arm clinical study is to evaluate the efficacy and safety of toripalimab in combination with axitinib for postoperative adjuvant therapy for non-clear renal cell carcinoma with high-risk recurrence factors.

NCT ID: NCT05768399 Recruiting - Asthma in Children Clinical Trials

The Role of Biomarkers in the Occurrence and Development of Asthma

Start date: July 4, 2023
Phase:
Study type: Observational

To study the expression level of biomarkers such as GITRL in peripheral blood of children with asthma and analyze their correlation with the severity of asthma. To study the predictive value of biomarkers level for the occurrence and development of asthma. And to provide supplementary detection means and predictive indicators for the diagnosis of asthma and the severity of asthma.

NCT ID: NCT05768321 Recruiting - Clinical trials for Advanced Solid Tumors

Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Start date: November 4, 2021
Phase: Phase 1
Study type: Interventional

The overall objective of this Phase 1 study is to evaluate the safety, Pharmacokinetics (PK), and anti-tumor activity of daily oral dosing with GEC255 tablets in subjects with advanced solid tumor with Kirsten Rat Sarcoma (KRAS) p.G12C mutation. To determine the recommended Phase 2 dose (RP2D) based on assessments of multiple dose escalation and expansion in target cohorts.

NCT ID: NCT05768204 Recruiting - Severe Pneumonia Clinical Trials

Research on the Treatment of Severe Community-acquired Pneumonia in Children

Start date: March 10, 2023
Phase: Phase 4
Study type: Interventional

The need for glucocorticoid therapy in children with severe community-acquired pneumonia in the acute phase of the disease remains unclear. The implementation of this study could provide strong evidence on the need for adjuvant glucose therapy in children with severe community-acquired pneumonia.

NCT ID: NCT05767866 Recruiting - Treatment Clinical Trials

Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Start date: March 30, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study aimed to evaluate the safety and preliminary efficacy of YK-029A, a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in treated or untreated patients with advanced non-small cell lung cancer (NSCLC).

NCT ID: NCT05767710 Recruiting - Sarcopenia Clinical Trials

A Study of the Telerehabiliation Intervention Effect of the Tai Chi Exercise on Elderly With Sarcopenia

Start date: April 10, 2023
Phase: N/A
Study type: Interventional

Sarcopenia is an age-related disease characterized by a progressive decrease in skeletal muscle content and loss of muscle function. Tai Chi exercises have been shown to improve skeletal muscle mass in elderly people suffering from sarcopenia. However, offline interventions are a very labor- and financial-intensive approach. Therefore, researchers designed an artificial intelligence-assisted program and Tai Chi exercise format to investigate whether a remote rehabilitation approach could replace face-to-face interventions

NCT ID: NCT05767528 Recruiting - Clinical trials for Muscle-Invasive Bladder Carcinoma

Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection

Start date: December 8, 2022
Phase:
Study type: Observational

In this study, investigators plan to conduct the 3D in vitro culture PTC drug sensitivity testing of fresh tumor specimen which obtained by endoscopic biopsy or other methods. Through assessing the consistency between the testing results and the patients' neoadjuvant treatment outcomes, they would evaluate the accuracy of PTC drug sensitivity testing and its application value in the individualized precision medicine for muscle-invasive bladder carcinoma.